Fiera Capital Corp Sells 17,692 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Fiera Capital Corp lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 499,109 shares of the company’s stock after selling 17,692 shares during the period. Fiera Capital Corp’s holdings in Neurocrine Biosciences were worth $68,128,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Golden State Wealth Management LLC bought a new position in Neurocrine Biosciences in the 4th quarter worth $25,000. Brooklyn Investment Group lifted its stake in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares in the last quarter. Blue Trust Inc. boosted its holdings in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares during the period. R Squared Ltd purchased a new stake in Neurocrine Biosciences in the 4th quarter worth $61,000. Finally, UMB Bank n.a. increased its stake in Neurocrine Biosciences by 211.6% in the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after buying an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kyle Gano sold 65,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the transaction, the chief executive officer now directly owns 135,392 shares of the company’s stock, valued at $19,157,968. This represents a 32.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Kevin Charles Gorman sold 146,105 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30. Following the transaction, the director now owns 514,596 shares in the company, valued at $76,911,518.16. This trade represents a 22.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 226,647 shares of company stock worth $33,186,271. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Up 0.3 %

NASDAQ NBIX opened at $117.18 on Thursday. The stock has a market cap of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a fifty day simple moving average of $138.49 and a two-hundred day simple moving average of $131.02.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Wall Street Analyst Weigh In

NBIX has been the subject of a number of recent analyst reports. Canaccord Genuity Group dropped their price objective on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a research note on Friday, February 7th. HC Wainwright dropped their price target on Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating for the company in a research note on Friday, February 7th. BMO Capital Markets reduced their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Morgan Stanley boosted their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Finally, Guggenheim cut their target price on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a research note on Monday. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.